Guide to the use of cancer chemotherapeutic agents.
D000477:Alkylating Agents / Q000627:therapeutic use; D000493:Allopurinol / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000963:Antimetabolites / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001215:Asparaginase / Q000627:therapeutic use; D001377:Azaserine / Q000627:therapeutic use; D001380:Azauridine / Q000627:therapeutic use; D001761:Bleomycin / Q000627:therapeutic use; D002166:Camptothecin / Q000627:therapeutic use; D002330:Carmustine / Q000627:therapeutic use; D002455:Cell Division; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D003609:Dactinomycin / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D007700:Kinetics; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D014227:Triazines / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000477:Alkylating Agents; D000903:Antibiotics, Antineoplastic; D000963:Antimetabolites; D000970:Antineoplastic Agents; D009588:Nitrogen Mustard Compounds; D014227:Triazines; D003561:Cytarabine; D001761:Bleomycin; D003609:Dactinomycin; D011344:Procarbazine; D014750:Vincristine; D000493:Allopurinol; D001380:Azauridine; D004317:Doxorubicin; D001377:Azaserine; D003520:Cyclophosphamide; D001215:Asparaginase; D005472:Fluorouracil; D002330:Carmustine; D002166:Camptothecin; D003630:Daunorubicin